Document Detail


Resveratrol down-regulates survivin and induces apoptosis in human multidrug-resistant SPC-A-1/CDDP cells.
MedLine Citation:
PMID:  19956893     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We studied the effect of resveratrol treatment on multidrug-resistant human non-small cell lung cancer cells. Human multidrug-resistant SPC-A-1/CDDP cells were treated with resveratrol at a concentration of 25, 50, or 100 microM in in vitro studies and nude mice were implanted with multidrug-resistant SPC-A-1/and fed a special diet that included resveratrol at a dose of either 1 g/kg/day or 3 g/kg/day in in vivo studies. No adverse toxicological effects of resveratrol treatment were observed. The rate of cell proliferation, apoptosis ratio, cell cycle phase distribution, IC50 values of cisplatin, gefitinib, and paclitaxel, implanted tumour volume, and expression of survivin in resveratrol-treated and control mice were then determined. Resveratrol significantly inhibited the proliferation of SPC-A-1/CDDP cells, induced apoptosis, arrested the cell cycle phase between G0-G1 and S phase or at the G2/M phase, decreased the IC50 values of multiple chemotherapeutic drugs, and showed anti-tumour effects in nude mice that had been implanted with SPC-A-1/CDDP cells. In additional, resveratrol affected the proliferation of SPC-A-1/CDDP cells in a dose- and time-dependent manner. Expression of survivin in SPC-A-1/CDDP cells decreased after they were treated with all concentrations of resveratrol and resveratrol was also found to have a dose-dependent effect on survivin expression. Resveratrol can induce apoptosis in multidrug-resistant human NSCLC SPC-A-1/CDDP cells by down-regulating the expression of survivin.
Authors:
Weiguo Zhao; Pengtao Bao; Haowen Qi; Houcheng You
Related Documents :
17356823 - Modification of multidrug resistance of tumor cells by ionizing radiation.
1358293 - P-glycoprotein-mediated multidrug resistance and cytotoxic effector cells.
17579893 - Binding of the hop (humulus lupulus l.) chalcone xanthohumol to cytosolic proteins in c...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Oncology reports     Volume:  23     ISSN:  1791-2431     ISO Abbreviation:  Oncol. Rep.     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2009-12-03     Completed Date:  2010-03-19     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  9422756     Medline TA:  Oncol Rep     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  279-86     Citation Subset:  IM    
Affiliation:
Department of Respiratory Medicine, The Second Affiliated Hospital of Chinese PLA General Hospital, Beijing, P.R. China. zhaowg2008@qq.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Apoptosis*
Cell Cycle
Cisplatin / pharmacology*
Dose-Response Relationship, Drug
Down-Regulation*
Drug Resistance, Multiple*
Drug Resistance, Neoplasm*
Drug Screening Assays, Antitumor
Humans
Inhibitor of Apoptosis Proteins
Inhibitory Concentration 50
Mice
Mice, Nude
Microtubule-Associated Proteins / biosynthesis*
Stilbenes / pharmacology*
Chemical
Reg. No./Substance:
0/BIRC5 protein, human; 0/Inhibitor of Apoptosis Proteins; 0/Microtubule-Associated Proteins; 0/Stilbenes; 15663-27-1/Cisplatin; Q369O8926L/resveratrol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer p...
Next Document:  Pyrogallol-induced endothelial cell death is related to GSH depletion rather than ROS level changes.